


AMENDMENTS TO THE CLAIMS

Claims 1-9 (Cancelled)

10. (Previously Presented) A compound represented by the formula (I)



wherein

R^1 is lower alkyl-C(O)NR³R⁴,

R^2 is hydrogen, lower alkyl, halogen, lower alkoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, amino or cyano, and

R^3 and R^4

may be the same or different, and each is hydrogen, lower alkyl or lower alkenyl, or R^3 and R^4 may bind with an adjacent nitrogen atom to form a saturated nitrogen-containing hetero ring (the hetero ring may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy),

a racemic mixture thereof, an enantiomer corresponding thereto or a pharmaceutically acceptable salt thereof.

11. (Previously Presented) The compound of claim 10, wherein R^2 is hydrogen, a racemic mixture thereof, an enantiomer corresponding thereto or a pharmaceutically acceptable salt thereof.

12. (Previously Presented) The compound of claim 10, wherein R^1 is lower alkyl-C(O)NR³R⁴ (either R^3 or R^4 is hydrogen) or lower alkyl-C(O)NR³R⁴ wherein R^3 and R^4 bind with an adjacent nitrogen atom to form a saturated nitrogen-containing hetero ring (the hetero ring may be substituted with lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy), a racemic mixture thereof, an enantiomer corresponding thereto or a pharmaceutically acceptable salt thereof.

13. (Previously Presented) The compound of claim 10, which is
(R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzoimidazol-1-yl}-N-methylacetamide,
a racemic mixture thereof, an enantiomer corresponding thereto or a pharmaceutically acceptable salt thereof.

Claims 14-27 (Cancelled)

28. (Previously Presented) A pharmaceutical composition comprising an effective amount of the compound of claim 10, a racemic mixture thereof, an enantiomer corresponding thereto or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.